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ABSTRACT We report that dendritic cells (DC) are necessary
and potent accessory cells for anti-sheep erythrocyte responses in
both mouse and man. In mice, a small number of DC (0.3-1% of
the culture) restores the response of B/T-lymphocyte mixtures to
that observed in unfractionated spleen. An even lower dose (0.030.1% DC) is needed if the T cells have been primed to antigen.
Responses are both antigen and T cell dependent. Selective depletion of DC from unfractionated spleen with the monoclonal antibody 33D1 and complement ablates the antibody response. In
contrast to DC, purified spleen macrophages are weak or inactive
stimulators. However, when mixed with DC, macrophages can
increase the yield of antibody-secreting cells about 2-fold. In man,
small numbers (0.3-1%) of blood DC stimulate antibody formation in vitro. Purified human monocytes do not stimulate but in
low doses (1% of the culture) inhibit the antibody response. Likewise, selective removal of human monocytes with antibody and
complement enhances or accelerates the development of antibody-secreting cells. We conclude that DC are required for the
development of T-dependent antibody responses by mouse and
human lymphocytes in vitro.

Dendritic cells (DC) are specialized stimulators, or accessory
cells, for the immune response (reviewed in refs. 1 and 2). Most
of the work in this and other laboratories has focused on T-lymphocyte responses. We have now studied the primary antibody
response to sheep erythrocytes (SRBC). DC prove to be effective stimulators of antibody formation in both mouse and human lymphocyte cultures. In contrast, mononuclear phagocytes
are weak or inactive. Human monocytes in small numbers (1%)
inhibit the development of antibody-secreting cells. This may
explain the prior difficulties in initiating human B-cell responses in vitro.
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MATERIALS AND METHODS
Animals. Mice of either sex, 6-10 wk of age, were used. Swiss
mice were from The Rockefeller University, whereas (A X B6)
F1, (DBA/2 X BALB/c) F1, and (BALB/c X C57BL/6) F1 were
from The Trudeau Institute (Saranac Lake, NY).
Antigen. SRBC and ox erythrocytes (Colorado Serum, Denver, CO) were stored in Alsever's at 4°C and used within 2 wk
of shipment.
Antibodies. 33D1 (3, 4) and B21-2 (5) are rat monoclonal antibodies specific for mouse DC and I-Abd antigens, respectively. TIB-99 is a monoclonal anti-mouse thy-1.2 (6) obtained
from the American Type Culture Collection (Rockville, MD).
3C10, BA-1, and Leu-1 are mouse monoclonal antibodies that
react with human macrophages (MO), B cells, and T cells, respectively, but not with DC (7).
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Table 1. DC stimulate the development of antibody-forming cells
PFC per culture
Exp. Exp. Exp. Exp. Exp. Exp.
Cells
1
2
3A
3B
4A
4B
518
288
410
Spleen
1,847 491 3,026
G-10
- DC
13
3
7
34
0
91
+ 0.01%DC
742
47
703
13
+ 0.03% DC
87
67
1,621
2,119
+ 0.10% DC
162
91
173
2,459
2,567
+ 0.15% DC
60
+ 0.30%DC
385
263
3,644 317 3,309
+ 0.50% DC
720
+ 1.0% DC
777
792
472 3,015
4,165
- + 1.5% DC
1,653
+ 3.0% DC
813
504 2,233
4,743
Unfractionated spleen cells or Sephadex G-10 nonadherent spleen cells
(primarily B and T lymphocytes) (5 x 106) supplemented with varying
doses of DC were cultured for 4 days with 5 x 106 SRBC as antigen.
Values given are direct PFC; the standard deviation ofthe plaque assay
was <15%. The PFC response in the absence of SRBC ranged from 3136. In experiments 3 and 4, the DC were tested for accessory function
on unprimed spleen (part A) or spleen from mice primed with 4 x 106
SRBC intraperitoneally 4 days previously (part B), a dose that primes
T cells primarily (15).

Cell Preparation. Spleen suspensions were prepared as described, including passage over Sephadex G-10 (Pharmacia) to
yield accessory cell-dependent B/T lymphocyte mixtures (8).
The accessory cells used to reconstitute antibody responses were
purified DC (80-90% pure; ref. 9) or MO-DC adherent cell
mixtures (4). These adherent cells and unfractionated spleen
were depleted of DC with 33D1 antibody and rabbit complement (C; ref. 4). Because the level of DC in spleen is so low
(<1%), we monitored the efficacy of the depletion procedure
by microscopic observation of the spleen adherent component
(2, 4). 33D1 and C reduced the frequency of DC from 10-40%
of adherent cells to 0-3%.
Human peripheral blood mononuclear cells and plastic-adherent cells were prepared as described (7, 10). Enriched populations (>97% pure) of monocytes were plastic-adherent cells
that remained attached after overnight culture (7, 10). DC (3070% pure by cytologic criteria) were obtained from adherent
cells that had detached from the plastic surface after overnight
culture and had been treated with monoclonal anti-monocyte
and lymphocyte antibodies to enrich for DC (7). Selective depletion of monocytes from blood mononuclear cells was done
with 3C10 antibody and C. This killed >95% of monocytes, as
judged by nonspecific esterase staining and by cytology (7), and
Abbreviations: DC, dendritic cell(s); SRBC, sheep erythrocyte(s); PFC,
plaque-forming cell(s); C, complement; MO, macrophages/monocytes.
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Table 2. Antibody responses induced by DC are antigen
dependent and specific
Number of anti-sheep or anti-ox PFC in

ON

800

T

.CI

Erythrocytes
used as
antigen
None
Sheep
Ox

G-10 nonadherent

G-10 nonadherent
responders + 0.5% DC

responders

Anti-sheep Anti-ox Anti-sheep
Anti-ox
25/8
38/10
61/10
75/19
20/4
29/15
1,553/31
298/20
19/10
43/12
584/31
2,261/80
Sephadex G-10 nonadherent spleen cells were stimulated with SRBC
or ox erythrocytes in the absence (left) or presence (right) of 0.5% purified DC. At day 4, PFC responses were measured in both SRBC and
ox erythrocyte plaque assays. Data are means ± SD of triplicate cultures. The degree of sheep and ox crossreactivity in vitro is similar to
that observed with immunization in situ (16).

the populations remained monocyte-depleted for 9 days in culture. Human B/T lymphocyte mixtures, which required accessory cells to generate antibody responses, were obtained by
three techniques: sedimentation in self-generated Percoll
(Pharmacia) gradients (11); passage over Sephadex G-10 columns as above (8); and two adherent cell depletions on plastic
(10).
Culture Conditions. For mouse cultures we used RPMI 1640
(GIBCO) with 10% heat-inactivated fetal calf serum (HiClone,
Sterile Systems, Logan, UT), 50 ,uM 2-mercaptoethanol, and
20 ,ug of gentamycin sulfate per ml. Graded doses of irradiated
accessory cells were added to 5 X 106 responders and cultured
for 4-5 days with or without 5 X 106 SRBC in 16-mm wells and
a total volume of 1.2 ml.
For human cells we used RPMI 1640 with 20% fetal serum,
gentamycin, 2-mercaptoethanol, 25 mM Hepes, and 2 mM Lglutamine. Although not shown in Results, isologous plasma
[15% (vol/vol)] could be used instead of fetal calf serum for DCmediated primary anti-SRBC responses. Cells (2.5 x 106) were
cultured in 16-mm wells for 6-12 days with or without an equal
number of SRBC in a total volume of 1.2 ml. After 5 days, the
cultures were fed daily with 50 ,lI of culture medium.
Plaque-Forming Cells (PFC). Direct or IgM antibody-secreting cells were counted with a plaque assay in agarose gel as
described (8).
RESULTS
DC Induce Plaque-Forming Responses in Nonadherent
Mouse Spleen Cells. Spleen cells passed over Sephadex G-10
require accessory cells for the development of antibody reTable 3. Selective elimination of DC with 33D1 monoclonal
antibody and C ablates antibody-forming responses
by mouse spleen
PFC response of spleen treated with
Exp.
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1
2
3
4
5
6

No C

No Ab
C heated

-

-

-

-

714
518
203
1,094

-

-

128
894

C fresh

1,390
2,483
561
429
212
1,110

No C
-

33D1
C heated
-

-

-

-

-

164
1,372

168
1,230

C fresh
17
37
123
19
23
10

Spleen cells were exposed to no antibody (Ab) or 33D1 anti-DC Ab
with either no C, heated (56°C, 1/2 hr) C, or active C. The cells were washed
and cultured for 4 days with SRBC as antigen. Values shown are PFC
per culture. Standard deviations were all <15%. PFC responses in the
absence of SRBC were <10% of those listed. In experiment 3, the 33D1/
active C cells were also supplemented with 3 x 104 DC and shown to
develop 408/39 PFC.
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FIG. 1. DC reconstitute the response of 33Dl/C-treated spleen cells.
Graded doses of DC were added back to whole spleen that had been
treated with 33D1 monoclonal antibody and C. PFC were measured with
(-*) or without --) SRBC antigenic stimulation. Control PFC
responses were 1,048 190 (no antibody, no C) and 839 203 (C only).
±

±

(8, 12-14). Our first experiments showed that purified
DC provided the accessory cell requirement for the generation
of PFC (Table 1). As few as 0.3-1% DC induced responses
comparable to or greater than that of whole spleen. If the T
cells were primed with a low dose of SRBC in situ, the secondary response needed only 0.03-0.1% DC (Table 1, experiments 3 and 4).
The DC-stimulated PFC response was antigen dependent
(Table 1) and specific (Table 2), as demonstrated by comparing
the responses to SRBC and ox erythrocytes. In 20 consecutive
experiments (not shown), DC did not stimulate an anti-SRBC
antibody response if T cells had been depleted from the Sephadex G-10 nonadherent population with anti-thy-i monoclonal
antibody and C. We conclude that DC are potent stimulators
of antigen- and T-cell-dependent PFC responses.
Selective Removal of DC Ablates PFC Responses in Unfractionated Spleen. The need for DC was verified by killing
these cells with a specific monoclonal antibody (33D1; refs. 3
and 4) and C. Selective elimination of DC with 33D1 and C
ablated the antibody-forming capacity of mouse spleen (Table
sponses

Table 4. Selective elimination of DC with 33D1 monoclonal
antibody and C ablates the accessory function of spleen
adherent cells
PFC in cultures of

Exp.

Spleen
*

-*

Sephadex G-10 nonadherent spleen
C onlyt
No Ab, No Ct
33D1, Ct

1
11
400
13
408
395
17
2
943
0
1,413
1,313
15
27
210
3
845
7
4
12
720
760
160
0
5
150
786
0
440
188
6
12
561
7
259
56
1,317
1,179
1,413
227
8
410
7
323
13
PFC responses to SRBC were measured after 4 days of culture. Responding cells (5 x 106 per culture) were whole spleen or Sephadex G10 nonadherent spleen (B and T lymphocytes) reconstituted with spleen
adherent cells (3-10 x 104 per culture) that had been treated with no
antibody (Ab) or 33D1 anti-DC and C. Responses in the absence of SRBC
were 0-123 PFC. The spleen adherent cells were not irradiated, but in
experiments 3 and 4, irradiated cells were compared to unirradiated
cells and gave similar data. In experiments 2 and 8, adherent cells treated
with 33D1 in the absence of C were also tested and gave 1,383 and 293

PFC, respectively.
* No adherents.
t Adherents.
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FIG. 2. Purified spleen MO are not active accessory cells for the PFC
response. Cultured spleen adherent cells (SAC; 80% MO) were treated
with no antibody and C (o) or 33D1 anti-DC and C (.), irradiated, and
tested as accessory cells in PFC responses. Purified DC (A) were also
studied. The percentage of Ia-bearing M4 in the spleen adherent population was 35%, as determined by indirect immunofluorescence with
an Fab fragment of the monoclonal antibody B21-2. The control PFC
response for whole spleen is shown at the top left.

3). The function of these 33D1/C-treated spleen cells was reconstituted with small numbers of DC enriched by a technique
not requiring the 33D1 antibody (Fig. 1).
The Effects of Spleen MO on Murine PFC Responses. The
role of MO in PFC development was studied with 33D1- and
C-treated spleen adherent cells. Most of the remaining cells
were M4 that expressed Fc receptors, MO-restricted surface
antigens, and phagocytic capacity (2-4). These MO were inactive as accessory cells (Table 4). Suspensions of adherent cells
obtained after overnight culture were also tested. These mixtures of MO and DC were <20% as active as enriched DC (Fig.
2). Selective elimination of DC with 33D1 and C again removed most of the accessory function (Fig. 2).

0.1

0.1 0.3 1
Dose (%) of accessory cells in culture

0.3

1

3

10

3

10

FIG. 4. DC stimulate and monocytes, inhibit the human primary
PFC response. Plastic nonadherent, -peripheral blood mononuclear cells
were passed over Sephadex G-10 columns to provide accessory cell-dependent mixtures of human B and T lymphocytes. Cells (2.5 x 106)-were
cultured in 16-mm wells in the presence of graded doses of accessory
cells: a, purified monocytes obtained from 1-day cultures of adherent
cells that remained attached to plastic; o, adherent cells that were released from -plastic after 1 day of culture (mixtures of monocytes, lymphocytes, and DG); 9, enriched populations -of DC (> 70% by cytologic
criteria) that were depleted of monocytes, and lymphocytes with monoclonal antibodies and C; A, a fixed number of DC (0.3%) supplemented
with the doses of monocytes shown on the abscissa. PFC responses to
SRBC were measured at 7 and 9 days of culture. No PFC were detected
in the absence of SRBC.

To test for a possible synergism between MO and DC, we
added back-graded doses of purified DC to spleen MO that had
been treated with 33D I and C. The DC-mediated response was
increased about 2-fold when small numbers of MO (0.5-1%)
were present (Fig. 3).
Accessory Cell Requirements for Human PFC Responses.
Accessory cell-dependent, human blood B and T cells were
prepared in three ways (see Materials arnd Methods). As in mice,
small numbers (0.3-1%) of DC induced an anti-SRBC PFC response, whereas enriched populations of MO did not (Fig. 4,
Table 5). However, very low levels (0.1-0.3%) of monocytes
enhanced the DC-mediated response, whereas -higher levels
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Percent dendritic cells added to culture
FIG. 3. MO can enhance a DC-mediated PFC response. Sephadex G-10 nonadherent spleen was supplemented with graded doses of DC
(v--) or graded doses of DC and a constant number of MO (0*- ; spleen adherent cells treated with 33D1 antibody and C to eliminate DC).

Other data from these experiments are given in Table 4, experiments 1 and 2. PFC responses in the absence of antigen were <90 PFC per culture.
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Table 5. DC stimulate and monocytes inhibit the primary anti-SRBC response of human
blood lymphocytes
PFC response (with/without SRBC) stimulated by
MonocyteDC-enriched
enriched
Day
No
populations
populations
of
DC + 1%
accessory
Exp.
assay
cells
0.3%
1.0%
3.0%
monocytes
1.0%
1
40/0
32/0
NT
6
0/0
205/0
440/0
0/3
3/0
30/3
2
8
0/3
78/0
130/0
3
8
NT
NT
NT
93/0
0/0
33/0
4
7
11/0
150/0
0/0
3/0
0/0
67/0
5
7
61/0
215/0
5/0
9/0
0/0
103/0
5
9
89/0
289/0
0/0
0/0
0/0
205/0
Accessory cell-dependent, human peripheral blood lymphocytes were prepared by adherence to plastic
(experiment 1), sedimentation in dense Percoll (experiments 2 and 3), or passage over Sephadex G-10 columns (experiments 4 and 5). These B/T lymphocyte mixtures were cultured in the presence or absence
of SRBC and no accessory cells, DC-enriched populations, monocyte-enriched populations (see text), or
mixtures of DC (0.3% in experiments 2 and- 5; 1% in experiment 4) and 1% monocytes. Direct or IgM PFC
were measured on the indicated days. NT, not tested.

(1%) reproducibly inhibited PFC development (Fig. 4, Table
5).
The selective removal of monocytes enhanced PFC development in peripheral blood mononuclear cells; >95% of blood
monocytes could be removed with the 3C10 monoclonal antibody and C as described (7). Monocyte depletion had two consequences that depended on the cell donor. One result was that
the removal of monocytes allowed a PFC response to occur (e.g.,
Fig. 5, experiment 1). This finding was reproduced twice in this
donor and with one other donor. In a third donor (Fig. 5, experiment 2), monocytes repeatedly delayed rather than blocked
PFC development.

DISCUSSION
The antibody response to SRBC (17) was one of the first systems in which primary immune responses were generated in
culture. In addition to lymphocytes, successful immunization
required accessory cells, selected by adherence to glass or to
plastic (18-22). DC were discovered in studies aimed at characterizing the active adherent cell (23). DC were distinguished
and separated from. other adherent cells, principally. M , and
were shown to be active stimulators of several T-cell responses
(reviewed in refs. 1 and.2). We have returned to the primary
anti-SRBC response to demonstrate that DC are essential for

thymus-dependent B-cell development. Specifically, small
numbers (<1% of the culture) of purified DC are sufficient for
active PFC responses in both mouse and man (Tables 1 and 5).
Selective elimination of mouse DC with 33D1 monoclonal antibody and C removes.both the antibody response of whole spleen
(Table 3 and Fig. 1) and the accessory function of heterogeneous adherent populations (Table 4 and Fig. 2).
The effect of DC on antigen-specific responses most likely
involves helper T lymphocytes that are induced to grow or function (or both) in response to DC and antigen. Some of the helper
effects may not be antigen dependent, because DC are strong
stimulators of the syngeneic mixed leukocyte reaction, which
in turn results in the production of helper factors (24, 25). It is
also possible that DC can interact directly with B cells. For example, it is known that DC and T cells can physically aggregate
with developing B cells in vitro (ref. 26; unpublished data).
However, we still do not know if DC and B cells will cluster
independently of T lymphocytes.
The contribution of MO to antibody responses is complex
and entails three findings. First, enriched populations of mouse
spleen MO and human blood monocytes by themselves are weak
or inactive accessory cells for anti-SRBC responses (Tables 4
and 5; Figs. 2 and 4). Many, if not most, of the M 0 in our-test
populations expressed Ta antigens. Therefore, we could not
confirm the conclusion of numerous previous studies that Ia'
Experiment 2
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FIG. 5. Depletion of monocytes enhances human PFC responses. Blood mononuclear cells from two donors (experiments 1 and 2) were exposed

to3C10 anti-monocyte antibody and C (v) to eliminate >95% ofthe monocytes (asjudged by nonspecific esterase staining). Controls (e) were exposed
to C only (or in other experiments to antibody alone). PFC responses to SRBC were measured on successive days in cultures of 2.5 x 10q cells. Viable
cell recoveries (70% of the starting dose) were similar in all cultures. No PFC developed in, the absence of SRBC in one donor (A, experiment 1),
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MO are essential for antibody responses. Instead, the active Ia+
cell under our experimental conditions is the DC.
The second point is that a very small number of MO (<1%
of the culture) enhances the stimulation by DC (Figs. 3 and 4).
This increase can even be mediated by 1a- MO (12) and perhaps
by other la- cells, such as cultured fibroblasts (27, 28). Synergism may involve the production of interleukin 1 (29) or additional "trophic" effects on cell viability (30).
The third finding is that MO can inhibit the PFC response.
Inhibition is known to require relatively high numbers in mice
(2.5% of the culture; e.g., see refs. 22 and 30), but we find that
inhibition occurs at very low doses in man (1%; Table 5 and Fig.
4). The realization that monocytes inhibit and DC stimulate antibody formation has led us to test the effect of selective monocyte depletion on human anti-SRBC responses. Responses are
enhanced or accelerated after the elimination of most monocytes with a specific monoclonal antibody and C (Fig. 5). The
human PFC response (100-700 PFC at days 6-8) seems comparable to the murine system, because the number of B cells
that are cultured is about 10% of that used in murine systems.
Although SRBC is the only antigen we have studied, our data
indicate that the development of human antibody responses
can best be achieved by removing rather than adding monocytes, as has been assumed (31-33). This change in approach
toward in vitro immunization hopefully will permit the study
of primary B-cell responses in clinical samples and aid in the
development of B-cell hybridomas that secrete high levels of
human monoclonal antibodies.
This research was supported by Grants Al 13013 and CA 30198 from
the National Institutes of Health. R. M. S. is an Established Investigator
of the American Heart Association.
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